June 20, 2005

CELLADON ANNOUNCES DEVICE PARTNERSHIP WITH V-KARDIA PTY LTD, A COMPANY

OF THE BAKER RESEARCH INSTITUTE
Celladon and V-Kardia to Collaborate on Development of Percutaneous Delivery of Gene Therapy for
Heart Failure
La Jolla, CA- June 20, 2005- Celladon Corporation announced today that it has entered into an agreement with V-Kardia, a
company of The Baker Research Institute, under which V-Kardia will develop its V-Focus device for percutaneous delivery of
Celladon's gene therapy for congestive heart failure and supply devices to Celladon.
Under the terms of the agreement, V-Kardia will develop the device for Celladon's gene therapy product and provide devices
for Celladon's clinical trials in heart failure patients scheduled to commence in 2006. V-Kardia receives contract development
payments, payments for devices, and license fees including milestones and royalties on product sales. Celladon receives
options to use the V-Kardia system with five additional therapeutic targets for cardiovascular and other indications.
The partnership agreement follows on preclinical results announced June 2 at the American Association of Gene Therapy
conference in St Louis, where The Baker Research Institute presented data from V-Kardia's research collaboration with
Celladon in heart failure. V-Kardia's device was used to deliver Celladon's gene therapy targeting the Sarcoplasmic Reticulum
ATPase2a (SERCA2a) calcium cycling pathway in myocardium. In a sheep pacing model of heart failure, the gene therapy
treatments reversed the deterioration of heart function and essentially restored the cardiac function of the animals to normal
levels.
V-Kardia developed the V-Focus device based on the pioneering work of the Baker Research Institute. The system delivers
therapeutics to the heart in a closed loop system that includes special catheters, an oxygenator and perfusion pump. The
catheter technique is similar to methods currently used for coronary angioplasty, and is easily adapted by interventional
cardiologists.
"Celladon's research collaboration with V-Kardia has produced promising results and we're pleased to expand the partnership
to include clinical development and supply of the devices to Celladon," said Steven Brauer, COO of Celladon. "Celladon's
therapeutic candidate targets the SERCA2a pathway, and malfunction in this pathway is associated with progressive heart
failure. Percutaneous delivery assures applicability to a broad heart failure patient population, and the V-Kardia device is
important for minimizing dose and maximizing therapeutic effects of the combination Celladon's drug/device".
About Congestive Heart Failure
Congestive heart failure (CHF) is a serious condition in which the heart loses its ability to pump blood efficiently. According to
the National Heart, Lung and Blood Institute, about 5 million people in the United States alone have heart failure, and another
550,000 new cases are diagnoed each year. CHF contributes to or causes about 300,000 deaths annually. The disease is
most common in people aged 65 or older, women and African Americans.
About V-Kardia
V-Kardia is a cardiovascular device company spun-out from the Baker Heart Research Institute and is 100% owned by the
Institute. Incorporated in January 2005 it is the first company to be formed around intellectual property developed by the
Institute's scientists. V-Kardia has developed a percutaneous delivery system for delivering gene therapies and drugs directly
to the heart. It also has applications for other organs.
Contact: Steve Brauer
Tel. 858-366-4288
2223 Avenida de la Playa, Suite 206
La Jolla, CA 9203